Axsome Therapeutics, Inc. AXSM
We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. 10-K, Item 1
- Headquarters
- New York, NY
- CEO
- Herriot Tabuteau
- Next results
- around Jan 11, 2027
AXSM among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
22 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 23, 2026 against Feb 18, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Inventory growing faster than revenueInventory +77.6% ($15.7M to $27.9M) vs revenue +65.5% ($385.7M to $638.5M), +12.0 pts apart
-
Receivables +58.1% ($142.0M to $224.5M) vs revenue +65.5% ($385.7M to $638.5M), -7.5 pts apart
9 more checks with nothing to note
-
Cash from operations −$93.4M vs net income −$183.2M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Reserves for Variable Consideration - Commercial Managed Care
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
22 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
On May 8, 2025 (the “Closing Date”), we entered into a loan agreement (the “Blackstone Loan Agreement”) with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”), certain subsidiaries party thereto as guarantors,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
General political uncertainty may have an adverse impact on our operating performance and results of operations. In particular, the U.S. continues to experience significant political events that cast uncertainty on the U.S. and global financial and economic markets. For example, on October 1, 2025, the U.S. federal government commenced…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
Further, the FDA’s review of our regulatory submissions may be delayed in the future due to reasons beyond our control. FDA operations are affected by various factors, such as shifting government priorities, budgets and funding levels, authorization and payment of user fees, the ability to hire and retain key personnel, as well as other…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
For example, in early September 2025, following a presidential memorandum directing the FDA to “take appropriate action to enforce the Federal Food, Drug, and Cosmetic Act’s prescription drug advertising provisions, and otherwise ensure truthful and non-misleading information in direct-to-consumer (DTC) prescription drug…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $50.0M | $270.6M | $385.7M | $638.5M |
| Net income | −$187.1M | −$239.2M | −$287.2M | −$183.2M |
| Operating cash flow | −$116.5M | −$145.1M | −$128.4M | −$93.4M |
| Free cash flow | −$117.2M | −$145.7M | −$128.7M | −$93.9M |
Revenue, FY2020 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$638.5M ▲ 65.5% in FY2025−$183.2M in FY2025−$93.9M in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 2, 2026Mark Coleman (Director) adopted a 10b5-1 trading plan reported in the 10-Q, up to 30,721 shares, runs to Dec 31, 2027
-
Planned saleNov 2, 2026Ari Maizel (Chief Commercial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 9,000 shares, runs to Dec 31, 2027
-
8-KNov 2, 2026Quarterly results, Other events 8-K items 2.02, 8.01
-
10-QNov 2, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Axsome Therapeutics, Inc., New York, NY · from the 10-K filed Feb 23, 2026
We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes. Our innovative CNS portfolio is anchored by three U.S.
- Headquarters
- New York, NY
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AXSM/export.csv") into a cell.